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Introduction
Intracellular adhesion molecules 1 (ICAM-1) and
vascular cell adhesion molecules-1 (VCAM-1) are
members of the immunoglobulin superfamily. They
both participate in adhesion between cells. Soluble
forms of ICAM (sICAM) and VCAM (sVCAM) have
been previously identified [1]. Elevated serum levels
of sICAM, sVCAM and sE-Selectin have recently
been described in patients with cancers [2-8]. Sever-
al studies suggest that cell adhesion molecules
(CAMs) play an important role in cancer progression
and metastases [3,9,10]. Guzinska-Ustymowicz and
Kemona [11] indicated that evaluation of TGF beta
expression of protein in association with histological
parameters can be used as a parameter of the aggres-
siveness of pT1 CRC. Okulczyk et al. indicated no
significant correlations between the mutations of
codon 12 K- RAS gene and clinical features. Also no
correlation was observed with either Dukes or TNM
clinical advancement [12] 
Metastatic spread of cancer cells is a key event in
tumor progression and in determining the prognosis of
patients with malignant disease. Malignant cells
detached from the primary tumor penetrate into blood
or lymph vessels, survive in the circulation, and are
then arrested in the capillary endothelium of distant
organs, extravasate and grow as a secondary lesion
[13]. Therefore,  sICAM-1, sVCAM-1 and sE-selectin
interactions between endothelial and cancer cells seem
to be crucial for the successful development of metas-
tases. These interactions are modulated by a specific
cell surface receptor including selectins, integrins and
immmunoglobulin like family of cell adhesion mole-
cules [1]. 
It is now increasingly apparent that certain mem-
bers of these families of CAMs are involved in tumor
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progression. Angiogenesis is mediated by the soluble
forms of sE-selectin and sVCAM-1 [14]. E-selectin,
also known as endothelial leukocyte adhesion mole-
cule-1, is expressed on endothelial cells and may bind
cells that express specific carbohydrate ligand contain-
ing sialyl-Lewis residue [15]. CAMs expression have
been demonstrated on the endothelial cells of small
vessels at the invasive margin of tumor cells involved
in metastatic spread [9]. The soluble forms of CAMs
have previously been recognized. They have been
detected in the serum of patients with colorectal can-
cer, where high circulating levels are generally associ-
ated with more advanced and metastatic disease [3].
No study has documented serum levels of E-selectin,
ICAM-1 and VCAM-1 in patients with colorectal can-
cer after radical tumor resection. 
The aim of the present study was to assess the
effect of tumor advancement and malignancy grade on
the levels of soluble ICAM-1, VCAM-1 and E-selectin
depending on surgical treatment. 
Materials and methods
Patients. The study included 40 colorectal cancer patients (CRC)
without remote metastases (20 men and 20 women, aged 42 – 68
years), diagnosed and operated in the Department of General
Surgery at the J. Sniadecki's Hospital in Bialystok and in Depart-
ment of General and Endocrinological Surgery, Medical Universi-
ty in Bialystok, and 24 healthy subjects (control group) (19 men
and 5 women, aged 40 – 64 years) (Table 1). 
The diagnosis of CRC was based on clinical symptoms and
colonoscopy and abdominal ultrasound scanning. The patients
underwent surgical procedure of tumor resection with subsequent
regional lymphadenectomy. During surgery, samples (primary
tumor, lymph node metastasis) were collected and neoplastic
lesions were histopathologically verified. All patients had col-
orectal cancer. None of these patients received chemotherapy or
radiation therapy before and after surgical intervention. 
The CRC patients qualified for our study did not have any
other ailment that could affect the immune response. Those
patients who had a recent inflammatory or any acute infection
were excluded from the study. Clinical advancement was evalu-
ated based on TNM classification by Hutter and Sobin [14], while
tumor type and malignancy grade were determined by
histopathological analysis. The CRC patients were divided into
two groups: A – 22 patients in stages I and II without metastases
(T1-2N0M0, malignancy differentiation grade G2, G3) and B – 18
patients with lymph node metastases (but not remote metastases)
in stage III of clinical advancement (T3N1-2M0, malignancy dif-
ferentiation grade G2, G3). Demographic data of the CRC
patients have been presented in Table 1.
Blood analysis. Peripheral venous blood samples in CRC patients
were collected twice: three days prior to surgery and 3 months after
surgery, into sterile glass tubes, in the morning after an overnight
fast.  The samples were allowed to coagulate at room temperature
for 30 min and then were centrifuged at 2500 g for 20 min. The
serum was separated and stored at -70°C until analysis. Before
analysis, samples were thawed slowly and mixed gently. 
The soluble forms of CAMs were measured in blood serum
using a commercially available immunoenzymatic method. Serum
sICAM, sVCAM and E-selectin concentrations were determined
using enzyme-linked immunosorbent assay (ELISA) kits (Parame-
ter; R&D Systems, Minneapolis, MN) according to procedures rec-
ommended by the manufacturer.
Ethical issues. The protocol was approved by the Medical Univer-
sity of Bialystok Bioethics Committee, according to Guidelines for
Good Clinical Practice (GCP) (R-I-003/325/2004). Only patients
who gave their informed written consent were enrolled in the
study.
Statistical analysis. Data are presented as means and standard
deviation (±SD). Nonparametric U Mann-Whitney test and Spear-
man correlation test were used for statistical analysis of the results.
The program STATISTICA 6.0 for Windows was applied. Differ-
ences were considered statistically significant for p<0.05. 
Results
Table 2 shows the means and standard deviation of
sICAM-1, sVCAM-1 and sE-selectin in the serum of
CRC patients and in the control group. Serum mean
concentrations of sICAM-1 in cancer cases and con-
trols were 366.1±114.1 and 306.4±98.2 ng/ml
(p=0.037), respectively; sVCAM-1 were 974.4±214.3
and 510.1±199.4 ng/ml (p=0.001), respectively. The
differences between the two groups were significant.
Serum concentration of sE-selectin was not signifi-
cantly higher in the cancer group compared to the con-
trol group; 88.2±34.3 and 68.2±26.3 ng/ml; p=0.074,
respectively (Table 2). 
To study the effect of surgical tumor removal on the
levels of the circulating cell adhesion molecules in all
CRC patients, we measured and compared sE-selectin,
sICAM-1 and sVCAM-1 concentrations before surgi-
cal treatment and 3 months after it. Radical resection
of primary tumor involved surgical removal of all or
part of the colon and resection of the regional lymph
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Table 1. Demographic and clinical characteristics of patients with
colorectal cancer (CRC) and healthy control group. Group A –
CRC patients in stage I and II of clinical advancement (T1-
2N0M0, malignancy differentiation grade G2, G3). Group B –
CRC patients in stage III of clinical advancement.  (T3N1-2M0,
malignancy differentiation grade G2, G3). Group C – control.
node. Only serum levels of sICAM and sVCAM, but
not sE-selectin, decreased significantly after radical
resection of the tumor compared with preoperative lev-
els; sICAM 366.4±114.0 ng/ml vs. 247.3±68.4 ng/ml
(p<0.001) and sVCAM 974.3±214.0 vs. 470.1±106.3
ng/ml (p<0.0001) (Table 3).
We compared the concentrations of sICAM-1,
sVCAM-1 and sE-selectin in the serum of CRC patients
between group A and B. We observed a significantly
higher concentration of sICAM (396.2±68.9ng/ml) and
sVCAM (1210.3±199.0 ng/ml) in the serum of the CRC
patients with lymph node metastases. There was a sig-
nificant difference between the two groups (Table 4). No
significant difference was observed in sE-selectin con-
centration in the serum of the CRC patients before surgi-
cal intervention (group A: 82.4±23.3 group B: 88.4±29.0
(Table 4). There was also no significant correlation of
serum sICAM-1, sVCAM-1 and sE-selectin levels in
CRC cases with patients' age or gender. However, the
preoperative levels of all the three adhesion molecules
were significantly correlated with disease stage and
lymph node involvement.
Disscusion
Adhesion molecules are thought to be essential for
maintaining a normal immune defense system in a
variety of important biological events including car-
cinogenesis and metastasis biology. It has been sug-
gested that the process of tumor metastasis includes
differential expression of adhesion molecules, with
some being over-expressed, others down-regulated
and some structurally changed, causing a loss of cell-
cell interaction which could facilitate metastasis.
Elevated serum levels of cell adhesion molecules
(CAMs) have been described in patients with cancers
[17]. In our research, like in the studies of other
authors [2], preoperative serum concentrations of
sICAM and sVCAM in CRC patients were significant-
ly higher compared to the control group, whereas no
differences were found regarding serum sE-selectin
levels. Similar results concerning sE-selectin were
obtained by other investigators, who concluded that
the level of sE- selectin cannot be a predictive marker
in colorectal cancer, although it may be useful in the
diagnosis of liver metastases [20]. 
We have confirmed the findings by Alexiou et al. [3]
and Kang et al. [21], who found elevated levels of
CAMs in CRC patients. In our study, the levels of serum
sICAM-1 and sVCAM-1 in healthy controls were simi-
lar to those reported by other authors [4,9,20,22,23].
These soluble forms of sICAM, sVCAM and sE-
selectin significantly correlated with tumor stage and
the development of metastases of colorectal cancer
[21,25]. In our study, there was a significant correlation
of serum sICAM-1 and sVCAM-1, but not sE-selectin,
with the disease stage, which can be explained by low
neoangiogenesis in the neoplastic tissue.
As revealed by many authors, these soluble forms
of CAMs significantly correlated with TNM stage and
the development of metastases of gastric cancer [2,25],
colorectal cancer [21], breast cancer [5,7], in urologi-
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Table 2. Serum levels of sICAM and sVCAM in the colorectal
cancer cases and healthy control group. sICAM-1 – soluble intra-
cellular adhesion molecule-1, sVCAM-1 – soluble vascular cell
adhesion molecule-1, sE-selectin – soluble E-selectin, both men
and women are incorporated.
Table 3. Serum levels of sICAM, sVCAM and sE-selectin in the
colorectal cancer cases before and after surgical intervention.
sICAM-1 – soluble intracellular adhesion molecule-1, sVCAM-1
– soluble vascular cell adhesion molecule-1, sE-selectin – soluble
E-selectin, both men and women are incorporated.
Table 4. Serum levels of sICAM, sVCAM and sE-selectin in CRC
patients before surgical intervention: group A – without metastases
and group B – with lymph node metastases. sICAM-1 – soluble
intracellular adhesion molecule-1, sVCAM-1 – soluble vascular
cell adhesion molecule-1, sE-selectin – soluble E-selectin. Values
were expressed as the means SD, both men and women are incor-
porated.
cal malignancies [6] and in chronic B-lymphocytic
leukemia [4]. Numerous investigations in clinical
diagnosis have been focused on the evaluation of the
adhesion molecule expression to identify the interac-
tion between tumor cells and host immune response.
The preoperative levels of sICAM-1, sVCAM-1, ele-
vated in our study, showed relatively high specificity,
but had low sensitivity for diagnosis of colorectal can-
cer. There was a significant correlation of serum
sICAM-1 and sVCAM-1 levels, but not sE-selectin,
with TNM stage and lymph node involvement. No sig-
nificant relationship was found between the concentra-
tions and patients' age or gender. The factors regulat-
ing CAMs in colorectal cancer are complex. The asso-
ciation among immunohistochemical CAM expres-
sion, tumor vascularity and leukocyte infiltration sug-
gests an important role for these molecules in host
immune response and in tumor progression [2]. 
We observed significantly higher concentrations of
sICAM and sVCAM in the serum of the CRC patients
with lymph node metastases. Metastatic spread of can-
cer cells is a key event in tumor progression and in
determining the prognosis of patients with malignant
disease. CAM expressions have been demonstrated on
endothelial cells of small vessels at the invasive mar-
gin of tumor cells involved in metastatic spread [9]. In
various vascular disorders, activated lymphocytes and
macrophages produce cytokines, of which interleukin-
1(IL-1), tumor necrosis factor (TNF-α) and interferon-
γ are the main inducers of adhesion molecule expres-
sion on endothelial cells [26].
We believe that the circulating sCAMs may have a
regulatory role, although their biological role has not
been completely elucidated. The migration of lympho-
cytes from intravascular system to tissue is a funda-
mental event in the immune response to an inflamma-
tory process and it is the result of specific interactions
of adhesion molecules on endothelium and their lig-
ands on lymphocytes. Since LFA-1 is the ligand for
ICAM-1 and it is involved in the initial steps of adhe-
sion of cytotoxic T lymphocytes to the target tumor
cells [27], we suggest that ICAM-1 shedding from
tumor cells could block binding of cytotoxic T lym-
phocytes to cancer. Additional loss of adhesion mole-
cules from activated endothelium could inhibit count-
er ligands on the tumor cells themselves, preventing
their adhesion to endothelium sites and thereby pro-
moting metastases. We have confirmed this assump-
tion, showing a correlation of the level of adhesion
molecules with tumor differentiation grade and the
process of metastasis. In gastric cancers, serum
sICAM-1 and sVCAM-1 levels decreased significant-
ly after radical tumor resection [3]. In our study, serum
levels of sICAM and sVCAM, but not sE-selectin,
were found to be significantly higher in patients before
surgical treatment for CRC compared to those after
radical resection. In vitro studies have shown that at
least ICAM-1 expressed by tumor cells is shed in the
cell culture supernatants [28], which may explain our
observations.
These findings seem to suggest that serum concen-
trations of sCAMs can reflect tumor progression and
metastases, and may be clinically useful. We think that
an improved understanding of the mechanisms of
membrane shedding of sICAM, sVCAM and sE-
selectin, their effect on the host immune response,
their relationship to disease stage and lymph node
involvement is required to delineate their role in tumor
progression. 
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